Shifting strategy, Coherus buys rights to experimental cancer drug

The biosimilar maker will develop an immunotherapy rival to Merck's Keytruda via a deal with China's Junshi Biosciences.

By Jonathan Gardner • Feb. 1, 2021

Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca

AstraZeneca's decision to spin out Viela Bio in 2018 paid off with a drug approval, an initial public offering, and now an acquisition that will net the pharma close to $800 million. 

By Jacob Bell , Ben Fidler • Feb. 1, 2021

With latest deal, Merck wades into cell therapy for cancer

A small upfront payment gives Merck access to a program from Artiva Biotherapeutics that aims to create "off-the-shelf" CAR-NK cell therapies for solid tumors.

By Kristin Jensen • Jan. 28, 2021

Lilly strikes deal to acquire drug for chronic pain

The experimental treatment from Asahi Kasei Pharma adds to Lilly's pipeline of drugs for pain, including a non-opioid medicine now under review at the FDA. 

By Ned Pagliarulo • Jan. 28, 2021

Lilly allies with Vir, GSK as coronavirus variants raise worries about antibody drugs

The emergence of new variants has made antibody drug combinations, which are harder for the virus to evade, more important and led to a unique partnership between a trio of drugmakers.

By Ben Fidler • Jan. 27, 2021

Lilly expands its cancer drug work with bet on dual-acting antibodies

An alliance with Merus, a Dutch biotech, continues Lilly's push to revitalize its oncology research under the leadership of former Loxo Oncology executives.

By Ben Fidler • Jan. 19, 2021

Dana-Farber launches venture fund targeting incurable cancers

Binney Street Capital plans to invest in eight to 10 companies over the next three years. Developing new drugs will be a core focus, though investments could also go toward health services, digital health or diagnostics.

By Jacob Bell • Jan. 15, 2021

5 trends in biotech dealmaking to watch in 2021

Brain drugs, private equity players and blank-check companies are just some of the things deal experts say they'll be keeping an eye on this year.

By Jacob Bell • Jan. 13, 2021

Celgene's cell therapy spinout nets $292M from blank-check merger

With additional financing, Celularity will have $372 million to back development of off-the-shelf treatments for cancer and autoimmune diseases.

By Jonathan Gardner • Jan. 8, 2021

Leading $105M biotech funding, Bayer deepens cell therapy investment

A Series B investment in Senti Biosciences will support the startup's research on off-the-shelf candidates, as Bayer places another bet on cell therapy.

By Jonathan Gardner • Jan. 6, 2021

Biogen pushes further into eye gene therapy with new deal

Partnering with German biotech ViGeneron bolsters Biogen's pipeline of drugs for eye diseases, which includes assets acquired through its buyout of Nightstar Therapeutics.

By Kristin Jensen • Jan. 6, 2021

Roche adds to RNA drug deal streak with Ribometrix partnership

The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules.

By Ben Fidler • Jan. 6, 2021

Dewpoint forges another big pharma partnership — and a potential rivalry

The biotech, which works in the emerging research field of biomolecular condensates, is teaming up with Pfizer to find new treatments for a rare type of muscular dystrophy.

By Jacob Bell • Jan. 6, 2021

Merck signs $356M deal to supply US with experimental coronavirus drug

The drugmaker spent $425 million a month ago to acquire the biotech developer of the treatment, which tamps down on the body's inflammatory response to viral infections.

By Jonathan Gardner • Dec. 23, 2020

Vertex teams up with Skyhawk, leaning on another biotech in bid to diversify

Following a string of deals in edgy, unproven fields of scientific research, Vertex's latest deal involves chemical-based drugs that target RNA — an approach that's already attracted several large pharmas.

By Ben Fidler • Dec. 22, 2020

Changing identity, Agios to sell cancer drug business to Servier

Servier will pay Agios $1.8 billion upfront to acquire the biotech's approved leukemia treatment Tibsovo as well as the rest of its pipeline in cancer and early-stage research work.

By Ned Pagliarulo • Dec. 21, 2020

Novartis acquires a small biotech and its trio of brain drugs

More active in neuroscience than most pharmaceutical firms, Novartis would gain three experimental drugs for depression, schizophrenia and movement disorders through the deal.

By Jacob Bell • Dec. 17, 2020

Pharmacquired: What a surprise deal does for AstraZeneca and Alexion

The $39 billion tie-up would hand AstraZeneca five marketed rare disease drugs, including the pricey medicines Soliris and Ultomiris.

By Jacob Bell • Dec. 16, 2020

Lilly pays $880M for Prevail, pushing further into genetic medicine

The acquisition marks a significant bet by Lilly on gene therapy's potential to address tough-to-treat neurological disorders like Parkinson's disease.

By Jonathan Gardner • Dec. 15, 2020

Allogene, broadening its reach, helps start a biotech in China

The cell therapy developer is the second company in two days to form a joint venture with Overland Pharmaceuticals, which aims to bring new drugs to Asia.

By Ben Fidler • Dec. 15, 2020

AstraZeneca to buy Alexion for $39B

The deal launches AstraZeneca, a company that has been growing mostly because of newer drugs for cancer and diabetes, into the market for rare disease treatments.

By Jacob Bell • Updated Dec. 12, 2020

Lilly's coronavirus drug partner nails down one of biotech's largest IPOs

AbCellera Biologics, a developer of antibody drugs, has raised $483 million through one of the biggest initial public offerings for a biotech in recent years.

By Jacob Bell • Dec. 11, 2020

Bayer strikes a deal with Atara, wading deeper into cell therapy

A pact for two Atara programs continues the German pharma's efforts to use dealmaking to build a gene and cell therapy division.

By Ben Fidler • Dec. 7, 2020

Biogen stocks up on Sage's brain drugs in $3B deal

Biogen and Sage each face challenges. While executives from both companies said the deal could provide a boost, investors don't appear to be sold just yet.

By Jacob Bell • Updated Nov. 30, 2020

How Gilead finally spent its money

This year, the biotech spent about $27 billion trying to become a leader in cancer research. Executives who spoke to BioPharma Dive said there's still work to be done.

By Jacob Bell • Nov. 24, 2020